<!DOCTYPE html>
<html>
<head>
<meta name="viewport" content="width=device-width, initial-scale=1"/>
<script src="/scripts/aem.js" type="module"></script>
<script src="/scripts/scripts.js" type="module"></script>
<link rel="stylesheet" href="/styles/styles.css"/>
</head>
<body>
<header></header>
<main>
<div><h1 id="think-lokelma-for-its-demonstrated-efficacy1">Think LOKELMA for its demonstrated efficacy<sup>1</sup></h1></div>
<div>













<div class="cards-lokelma"><div><div><picture><source srcset="./images/icon-clock-lokelma.svg"><source srcset="./images/icon-clock-lokelma.svg" media="(min-width: 600px)"><img src="./images/icon-clock-lokelma.svg" alt="48-hour correction phase" loading="lazy"></picture><br><br>During 48-hour correction phase<sup>1*</sup><br><br><strong>88%</strong> of LOKELMA patients achieved <strong>normokalemia at 48 hours</strong><br><br>Reductions in potassium were observed <strong>1 hour</strong> after the first 10 g dose of LOKELMA<br><br><strong>Median time</strong> to normokalemia was <strong>2.2 hours</strong> with LOKELMA 10 g TID (baseline avg: 5.6; range 4.1–7.2 mmol/L)<br><br>ZS-004: 48-hour study<br>(open-label uncontrolled)</div></div><div><div><picture><source srcset="./images/icon-wave-lokelma.svg"><source srcset="./images/icon-wave-lokelma.svg" media="(min-width: 600px)"><img src="./images/icon-wave-lokelma.svg" alt="maintenance phase" loading="lazy"></picture><br><br>During maintenance phase (days 8–365)<sup>1†</sup><br><br><strong>75.6%</strong> of LOKELMA patients <strong>sustained normokalemia</strong><sup>‡</sup><br><br>Of the 70% of patients who were on RAASi therapy at baseline, <strong>~89%</strong> stayed on RAASi therapy<br><br>ZS-005: long-term study<br>(up to 12 months; open-label uncontrolled)</div></div></div></div>
<div><!-- Content source: Figma design node-id=677-6811 --><!-- Block: cards-lokelma --><!-- Created: 2025-10-30 --></div>
</main>
<footer></footer>
</body>
</html>